Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $227.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 478.79% year-over-year to $227.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $392.2 million (up 334.67% YoY) and the FY2025 annual result came in at $61.3 million, up 1270.81% from the prior year.
• Liabilities and Shareholders Equity climbed to $227.8 million in Q1 2026, from $65.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $227.8 million in Q1 2026 to a low of $4.5 million in Q3 2024.
• A 5-year average of $32.1 million and a median of $8.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 61.72% — and 2025, when it surged 1270.81%.
• Tracing DRUG's Liabilities and Shareholders Equity over 5 years: stood at $8.5 million in 2022, then plunged by 40.55% to $5.1 million in 2023, then jumped by 726.38% to $41.8 million in 2024, then soared by 55.89% to $65.2 million in 2025, then soared by 249.52% to $227.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $227.8 million (Q1 2026), $65.2 million (Q4 2025), and $61.3 million (Q3 2025), per Business Quant data.